Table 2.
Distribution of initial dose, median dose, dose modification, and reasons for treatment discontinuation
| <75 years (N = 397) | ≥75 years (N = 397) | P value | |
|---|---|---|---|
| Median starting dose, mg/day (IQR) | 800 (0.0) | 800 (400.0) | 0.2702 |
| Median daily dose, mg/day (IQR) | 538.5 (400.0) | 422.3 (458.2) | <0.0001 |
| Relative dose intensity, % | 69.4 ± 26.3 | 61.8 ± 28.0 | <0.0001 |
| Median duration of treatment, months (IQR) | 7.6 (9.9) | 5.6 (10.3) | 0.0123 |
| Dose modification, n (%) | |||
| Reduction | 222 (55.9) | 238 (60.0) | 0.2501 |
| Interruption | 164 (41.3) | 186 (46.9) | 0.1158 |
| Discontinuation | 253 (63.7) | 299 (75.3) | 0.0004 |
| Reason for discontinuation, n (%) | |||
| AEs | 147 (58.1) | 184 (61.5) | 0.4117 |
| Insufficient efficacy | 91 (36.0) | 79 (26.4) | 0.0155 |
| Others | 29 (11.5) | 44 (14.7) | 0.2609 |
AE adverse event, IQR interquartile range